BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
      • Artificial intelligence
    • Coronavirus
    • Israel
    • IVDs on the rise
    • Radiopharmaceuticals
    • Rise of obesity
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, November 30, 2023

Spinout

Home » Topics » Deals and M&A » Spinout
  • Heart scientific overlay
    Sep. 1, 2023

    Longaevus Technologies spins off Elastin Biosciences with focus on elastin-deficiency diseases

    Longaevus Technologies Ltd. has announced the spin-off of Elastin Biosciences following breakthrough preclinical results of three of its assets. Elastin Biosciences has successfully conducted experiments and identified three novel drug combinations that inhibit elastin degradation and foster its deposition, leading to an increase in elastin expression by 5-fold, and improving aortic elasticity in aged mice in vivo.
  • Epidermal growth factor receptor egfr
    June 9, 2023

    Emris Pharma to develop topical drug to treat skin toxicities caused by EGFR inhibitor use in cancer

    Emris Pharma, a recent spin-off of Hadasit Medical Research Services and Development Ltd. and Yissum Research Development Co., has started development of a new topical drug to treat skin toxicities caused by epidermal growth factor receptor (EGFR) inhibitors used to treat cancer.
  • March 8, 2023

    Ampersand Biomedicines set to develop programmable, more targeted therapeutics

    Flagship Pioneering Inc. has unveiled Ampersand Biomedicines, a company creating programmable medicines that are safer, more tolerable and effective by acting at the site of disease. Flagship has initially committed US$50 million to advance Ampersand's Address, Navigate, Design (AND) Platform and develop an initial pipeline of medicines across a range of disease areas.
Read More

Authors

  • Nuala Moran
  • Annette Boyle
More Authors
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing